Lundbeck, Forest Labs file Lexapro patent infringement suit against Caraco Pharmaceutical

By Lisa Kerner

Charlotte, N.C., July 11 - H. Lundbeck A/S, Forest Laboratories, Inc., and Forest Laboratories Holdings, Ltd. together have filed a lawsuit in the U.S. District Court for the Eastern District of Michigan against Caraco Pharmaceutical Laboratories, Ltd. for infringement of U.S. Patent No. 34,712 related to Forest's Lexapro product.

Caraco filed an abbreviated New Drug Application, including a paragraph 4 certification, for a generic equivalent to Lexapro.

"We believe the patent on Lexapro is valid and enforceable," Forest chairman and chief executive officer Howard Solomon said in a company news release. "Just as we did in our prior patent litigations against Ivax Pharmaceuticals and Alphapharm, we intend to prosecute this lawsuit vigorously."

H. Lundbeck, located in Copenhagen, Denmark, researches drugs for the treatment of central nervous system disorders.

Forest is a New York City-based pharmaceutical company manufacturing generic and prescription drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.